An observational study in Coronary Artery Disease, sponsored by Sahajanand Medical Technologies Limited. Completed at 26 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-12.
Sponsored by Sahajanand Medical Technologies Limited · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 365 studies in Coronary Artery Disease with a site in Germany — 46 open to participants now, 71 under way, 3 of them phase 3. Coronary Artery Disease · Germany.
Among the 365 studies in Coronary Artery Disease with a site in Germany, this one is the 38th largest by enrollment of the 117 observational ones that give a count, is one of 19 that started in 2020, is one of 117 observational ones, and was the 284th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →46 of the 365 studies in Coronary Artery Disease with a site in Germany are open now. Recruiting first, the newest first:
German Heart Institute · Sites in Germany
Ages 18+
Novartis Pharmaceuticals · Sites in Germany, United States, Australia and 2 more countries
Ages 18–80
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Emory University · Sites in Germany, United States, Serbia
Ages 18+
B. Braun Melsungen AG · Sites in Germany, Switzerland
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
365 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 32 · Phase 3 39 · Phase 4 47
First in 1999; this study’s year is marked. 19 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,200 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 265 across the 248 interventional studies, 550 across the 117 observational. Of the 237 that completed or were terminated, 56 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
171 of 365 have an industry lead sponsor. The 10 most frequent:
Sahajanand Medical Technologies Limited is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
Sahajanand Medical Technologies Limited has 7 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
14 of the studies in Coronary Artery Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04196712University Hospital, EssenEssen Coronary Artery Disease Registry | 2026-12-30 |
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
| NCT05540223Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System | 2027-02 |
| NCT06678490OrbusNeichSupport C Post-Market Registry | 2027-02 |
| NCT06535854Medtronic VascularPrevail Global Study | 2027-02 |
Add all 14 to your calendar (.ics) → With an account.
Among the 365 studies in Coronary Artery Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter, open-label, single-arm registry. The primary objective of this registry is to confirm the results of the Supraflex Cruz stent in real life all-comer patients (800 patients as in the Supraflex arm of the TALENT trial) and demonstrate that the Supraflex Cruz stent is not inferior to the BioFreedom stent in High Bleeding Risk (HBR) patients (400 patients) with respect to device oriented composite endpoint (DOCE) at 12 months. All patients will be followed up to 12 months after the index procedure.
All-comer patients affected by silent ischemia, stable angina or acute coronary syndrome (unstable angina and non-STEMI), who qualify for percutaneous coronary intervention (PCI), 400 patients of the population must qualify for HBR criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Supraflex Cruz Sirolimus-eluting Stent
Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care
Device Oriented Composite Endpoint (DOCE)
DOCE is a composite of cardiovascular death, myocardial infarction (MI) not clearly attributable to a non-target vessel and clinically-driven target lesion revascularization (TLR)
Time frame: 12 months
All death, cardiovascular death and non-cardiovascular death
Time frame: 6 months and 12 months
All myocardial infarction (MI)
Time frame: 6 months and 12 months
Target vessel MI and MI not clearly attributable to non-target vessel
Time frame: 6 months and 12 months
Clinically indicated target lesion revascularization (TLR)
Time frame: 6 months and 12 months
All target lesion revascularization (TLR)
Clinically and non-clinically indicated target lesion revascularization (TLR)
Time frame: 6 months and 12 months
All target vessel revascularization (TVR)
Clinically and non-clinically indicated target vessel revascularization (TVR)
Time frame: 6 months and 12 months
All revascularization
Any revascularization, TLR (clinically and non-clinically), TVR (clinically and non-clinically) and non-TVR
Time frame: 6 months and 12 months
Stent thrombosis (ARC2)
Time frame: 6 months and 12 months
Device success
Defined as deployment of the stents without system failure or device-related complication
Time frame: Up to 1 Day
Lesion success
Defined as the attainment of \< 50% residual stenosis of the target lesions post-PCI
Time frame: Up to 1 Day
Procedure success
Defined as all lesion successfully treated without the occurrence of DOCE during the hospital stay
Time frame: Up to 7 Days
Major bleeding (BARC 3 to 5) in the HBR population
Time frame: 6 months and 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2020 to primary completion in May 2022, 27 months.
Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's 27 months is close to that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sahajanand Medical Technologies Limited